度洛西汀联合喹硫平治疗躯体形式障碍的疗效观察  

作　　者：许振强[1] 

机构地区：[1]汕头大学精神卫生中心,广东515041

出　　处：《当代医学》2014年第26期5-6,共2页Contemporary Medicine

摘　　要：目的：探讨度洛西汀联合喹硫平治疗躯体形式障碍的疗效。方法选取2011年4月～2013年4月汕头大学精神卫生中心收治的符合条件的躯体形式障碍患者120例，随机均分为2组（n=60）。分别用度洛西汀联合喹硫平、单纯度洛西汀治疗，对比2组患者治疗前后HAMD评分、临床疗效及不良反应发生情况。结果（1）治疗前2组HAMD评分比较，差异无统计学意义；治疗第2、4、8周，观察组HAMD评分较对照组显著降低，差异有统计学意义（P＜0.05）；（2）疗程结束后，总有效率比较，差异有统计学意义（P＜0.05）；（3）2组不良反应发生情况比较，差异无统计学意义。结论度洛西汀联合喹硫平治疗躯体形式障碍效果较好，使用安全，稳定持久，可作为临床首选用药方案。Objective To investigate the effect of quetiapine combined duloxetine treating on somatoform disorders.Methods Selected 120 eligible patients with somatoform disorders, which were randomly divided into observation group and control group. The observation group were given duloxetine and quetiapine, and the control group were given duloxetine therapy, then compared the HAMD scores,clinical efficacy and adverse events of two groups of patients before and after treatment.Results （1） treatment The two groups showed no significant difference HAMD score before treatment, and after 4 and 8 weeks,the HAMD scores of observation group was significantly lower than the control group, the difference was statistically significant （P〈0.05）; （2）After treatment, total effective of the two groups have difference,and the difference was statistically significant （P〈0.05）; （3）The incidence of adverse reactions of the two groups was no significant difference.Conclusion Duloxetine combined quetiapine treat on somatoform disorders were better, safer, more stable and durable than other treatment, it can be used as the preferred clinical treatment program.

关 键 词：度洛西汀 喹硫平 躯体形式障碍 

分 类 号：R749.2[医药卫生—神经病学与精神病学]